Jounce Therapeutics (JNCE) Stock Price, News & Analysis

Company Overview

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Key Stats

• Today's Range: $1.88 to $1.88
• 50-Day Range: $1.84 to $1.94
• 52-Week Range: $0.58 to $5.87
• Volume: 169,314 shs
• Average Volume: 2.46 million shs
• Market Capitalization: $98.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

JNCE Stock Analysis - Frequently Asked Questions

How were Jounce Therapeutics' earnings last quarter?

Jounce Therapeutics, Inc. (NASDAQ:JNCE) issued its earnings results on Thursday, November, 4th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.15.

When did Jounce Therapeutics IPO?

Jounce Therapeutics (JNCE) raised $76 million in an IPO on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

What other stocks do shareholders of Jounce Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Jounce Therapeutics investors own include CRISPR Therapeutics (CRSP), Exelixis (EXEL), Meta Platforms (META), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ), Novavax (NVAX) and OPKO Health (OPK).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 5/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:JNCE
• CIK: 1640455
• Web: www.jouncetx.com
• Phone: (857) 259-3840
• Fax: N/A
• Employees: 137
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-50,920,000.00
• Net Margins: N/A
• Pretax Margin: -61.93%
• Return on Equity: -30.90%
• Return on Assets: -26.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.37
• Quick Ratio: 8.37

Sales & Book Value

• Annual Sales: $82 million
• Price / Sales: 1.21
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.54 per share
• Price / Book: 0.53

Miscellaneous

• Outstanding Shares: 52,630,000
• Free Float: 48,993,000
• Market Cap: $98.94 million
• Optionable: Optionable
• Beta: 0.75